Lilly Breaks Ground on $3.5-Bn Injectables Mfg Site in US
Eli Lilly and Company has broken ground on a $3.5-billion manufacturing facility in Fogelsville, the Lehigh Valley, Pennsylvania, which will produce injectable medicines and devices. The new facility is part of Lilly’s previously announced $50-billion investment in US manufacturing by 2030.
The site will add capacity for obesity treatments, including for the company’s retatrutide, a single peptide with once-weekly subcutaneous administration with a triple mechanism of action that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase III clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, Type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic dysfunction-associated steatotic liver disease. The site is expected to be operational by 2031 and will create 850 high-skilled positions, such as engineers, scientists, operations personnel, and lab technicians, along with approximately 2,000 construction jobs as the site is built and brought online.
The new facility is one of 10 new US manufacturing sites that the company has announced since 2020 and one of four sites that will produce injectable medicines and devices. These 10 sites are:
- Four will make injectable medicines and manufacture devices: Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; and Lehigh Valley, Pennsylvania.
- Five will product active pharmaceutical ingredients (APIs): Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two sites in Lebanon, Indiana – Lebanon API and Lilly Medicine Foundry, which will also focus on new production methods and making medicines for clinical trials.
- One will make genetic medicines in Lebanon, Indiana; Lebanon Advanced Therapies.
In addition, in support of the community in which the facility will be built, Lilly will provide up to $1 million over five years to the Upper Macungie Township Community Fund to support an initiative to develop a new quality-of-life program for Lehigh Valley families, with a focus on nutrition and healthy living, fresh food access, health resources, and community programming.
Source: Eli Lilly and Company

